Is the ApoE polymorphism associated with dilated cardiomyopathy?

General Physiology and Biophysics

Volumn 25, Issue 1, 2006, Pages 3-10

  Jurkovicova, Dana ^a   Goncalvesova, E ^b   Sedlakova, B ^a   Hudecova, S ^a   Fabian, J ^b   Krizanova, O ^a  

^a INSTITUTE OF MOLECULAR PHYSIOLOGY AND GENETICS   (Slovakia)

^b NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

Author keywords

Apolipoprotein E; Dilated cardiomyopathy; Gene polymorphism

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ARTICLE; BLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; NEUROLOGIC DISEASE; POLYMERASE CHAIN REACTION; PROTEIN POLYMORPHISM;

ALLELES; APOLIPOPROTEINS E; CARDIOMYOPATHY, DILATED; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 33744465518     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Anker S., von Haehling S. (2004): Inflammatory mediators in chronic heart failure: An overview. Heart 90, 464-470
2. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Little S. P., Cummins D. J., Piccardo P., Ghetti B., Paul S. M. (1997): Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17, 263-264
3. Bouthillier D., Sing C. F., Davignon J. (1983): Apolipoprotein E phenotyping with a single gel method: Application to the study of informative matings. J. Lipid. Res. 24, 1060-1069
4. Bretsky P. M., Buckwalter J. G., Seeman T. E., Miller C. A., Poirier J., Schellenberg G. D., Finch C. E., Henderson V. W. (1999): Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 13, 216-221
5. Contois J. H., Anamani O. E., Tsongalis G. J. (1996): The underlying molecular mechanisms of apolipoprotein E polymorphism: Relationships to lipid disorders, cardiovascular disease and Alzheimer's disease. Clin. Lab. Med. 16, 105-123
6. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. (1993): Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923
7. DeKroon R. M., Mihovilovic M., Goodger Z. V., Robinette J. B., Sullivan P. M., Saunders A. M., Strittmatter W. J. (2003): ApoE genotype-specific inhibition of apoptosis. J. Lipid. Res. 44, 1566-1573
8. Guo L., LaDu M. J., Van Eldik L. J. (2004): A dual role for apolipoprotein E in neuroinflammation: Anti- and pro-inflammatory activity. J. Mol. Neurosci. 23, 205-212
9. Hallman D. M., Boerwinkle E., Saha N., Sandholzer C., Menzel H. J., Csazar A., Utermann G. (1991)A The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am. J. Hum. Genet. 49, 338-349
10. Hofman A., Ott A., Breteler M. M., Bots M. L., Slooter A. J., van Harskamp F., van Duijn C. N., van Broeckhoven C., Grobbee D. E. (1997): Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349, 151-154
11. Hubáček J. A., Pit'ha J., Adámková V., Škodová Z., Lánská V., Poledne R. (2003): Apolipoprotein E and apolipoprotein CI polymorphism in the Czech population: Almost complete linkage disequilibrium of the less frequent alelles of both polymorphisms. Physiol. Res. 52, 195-200
12. Incalcaterra E., Hoffmann E., Averna M. R., Caimi G. (2004): Genetic risk factors in myocardial infarction at young age. Minerva Cardioangiol. 52, 287-312
13. Kao J. T., Tsai K. S., Chang C. J., Huang P. C. (1995): The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis 114, 55-59
14. Liu S., Ma J., Ridker P. M., Breslow J. L., Stampfer M. J. (2003): A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 166, 323-329
15. Lynch J. R., Tang W., Wang H., Vitek M. P., Bennett E. R., Sullivan P. M., Warner D. S., Laskowitz D. T. (2003): APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem. 278, 48529-48533
16. Mahley R. W.F Rall S. C. Jr. (2000): Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1, 507-37
17. Muros M., Rodriguez-Ferrer C. (1996): Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Atherosclerosis 121, 13-21
18. Piedrahita J. A., Zhang S. H., Hagaman J. R., Oliver P. M., Maeda N. (1992): Generation of mice carrying a mutant Apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 89, 4471-4475
19. Plump A. S., Smith J. D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J. G., Rubin E. M., Breslow J. L. (1992): Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343-353
20. Poirier J. (A999): Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. Mol. Diagn. 4, 335-341
21. Poirier J. (2000): Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. N. Y. Acad. Sci. 924, 81-90
22. Ranjith N., Pegoraro R. J., Rom L., Rajput M. C., Naidoo D. P. (2004): Lp(a) and apoE polymorphisms in young South African Indians with myocardial infarction. Cardiovasc. J. S. Afr. 15, 1111-1117
23. Saraste A., Pulkki K., Kallajoki M., Heikkila P., Laine P., Mattila S., Nieminen M. S., Parvinen M., Vopipio-Pulkki L. M. (1999): Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur. J. Clin. Invest. 29, 380-386
24. Saunders A. M., Trowers M. K., Shimkets R. A., Blakemore S., Crowther D. J., Mansfield T. A., Wallace D. M., Strittmatter W. J., Roses A. D. (2000): The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochim. Biophys. Acta 1502, 85-94
25. Song Y., Atampfer M. J., Liu S. (2004): Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Inter. Med. 141, 137-147
26. Sparks D. L., Scheff S. W., Hunsaker J. C. 3rd., Liu H., Landers T., Gross D. R. (1994): Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88-94
27. Viitanen L., Pihlajamaki J., Miettinen R., Karkkainen P., Vauhkonen I., Halonen P., Kareinen A., Lehto S., Laakso M. (2001): Apolipoprotein E gene promoter (-219G/T) polymorphism is associated with premature coronary heart disease. J. Mol. Med. 79, 732-737
28. Wilson P. W., Myers R. H., Larson M. G., Ordovas J. M., Wolf P. A., Schaefer E. J. (1994): Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. J. Am. Med. Assoc. 272, 1666-1671
29. Wong W. M., Stephens J. W., Acharya J., Hurel S. J., Humphries S. E., Talmud P. J. (2004): The APOA4 T347S variant is associated with reduced plasma TAOS in subjects with diabetes mellitus and cardiovascular disease. J. Lipid Res. 45, 1565-1571